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(established status epilepticus, ESE) is a relatively
common emergency condition with several widely
used treatments. There are no controlled, ran-
domized, blinded clinical trials to compare the effi-
cacy and tolerability of currently available
treatments for ESE. The ESE treatment trial is
designed to determine the most effective and/or
the least effective treatment of ESE among
patients older than 2 years by comparing three
arms: fosphenytoin (fPHT) levetiracetam (LVT),
and valproic acid (VPA). This is a multicenter, ran-
domized, double-blind, Bayesian adaptive, phase
III comparative effectiveness trial. Up to 795
patients will be randomized initially 1:1:1, and
response-adaptive randomization will occur after
300 patients have been recruited. Randomization
will be stratified by three age groups, 2–18, 19–65,
and 66 and older. The primary outcome measure
is cessation of clinical seizure activity and improv-
ing mental status, without serious adverse effects
or further intervention at 60 min after administra-
tion of study drug. Each subject will be followed
until discharge or 30 days from enrollment. This
trial will include interim analyses for early success
and futility. This trial will be considered a success if
the probability that a treatment is the most effec-
tive is >0.975 or the probability that a treatment is
the least effective is >0.975 for any treatment. Pro-
posed total sample size is 795, which provides 90%
power to identify the most effective and/or the
least effective treatment when one treatment
arm has a true response rate of 65% and the true
response rate is 50% in the other two arms.
KEY WORDS: Comparative efficacy, Bayesian
design, Fosphenytoin, Levetiracetam, Valproic acid.
Objectives
There are approximately 120,000–180,000 episodes of
convulsive status epilepticus (SE) each year in the United
States, affecting individuals of all ages from very young to
the elderly (DeLorenzo et al., 1995, 1996; Shinnar et al.,
1997; Towne, 2007). The primary goal of status epilepti-
cus (SE) treatment is prompt termination of seizures
because rates of adverse consequences of SE, including
mortality, systemic complications, neurologic injury, and
refractoriness, increase with increasing seizure duration
(DeLorenzo et al., 1996; Neligan & Shorvon, 2010; Nor-
dli et al., 2012; Shinnar et al., 2012). Initial SE treatment
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with benzodiazepines is based on evidence from three
double-blind, randomized, controlled clinical trials (Trei-
man et al., 1998; Alldredge et al., 2001; Silbergleit et al.,
2012). Approximately one third of SE patients continue to
have seizures despite administration of adequate doses of
benzodiazepines; they are considered to have established
SE (ESE). There are no class I clinical trials comparing
the efficacy of currently available medications for the
treatment of ESE: phenytoin (PHT)/fos-phenytion
(fPHT), valproic (VPA), and levetiracetam (LVT). A
large-scale, retrospective analysis of protocol-driven
treatment of ESE suggested superiority of VPA over LVT;
PHTwas not statistically significantly different from other
two agents but was numerically poorer than VPA (Alvarez
et al., 2011). Fosphenytoin (fPHT) is the most commonly
preferred treatment and is recommended by current guide-
lines (Meierkord et al., 2010; Loddenkemper & Goodkin,
2011; Brophy et al., 2012). Experts, guideline writers,
Cochrane reviews, and professional associations have rec-
ommended a prospective randomized trial to determine
the best available treatment of ESE.
The primary objective of the Established Status Epi-
lepticus Trial (ESETT) is to determine the most effective
and/or the least effective treatment of benzodiazepine-
refractory SE among patients older than 2 years. There
are three active treatment arms: fPHT, LVT, and VPA.
Primary outcome is clinical cessation of status epilepti-
cus, without recurrent seizures, life-threatening hypoten-
sion or cardiac arrhythmia, or the use of additional
antiseizure medications within 60 min of the start of
study drug infusion. Clinical cessation of SE is defined
as the absence of clinical seizures and improving mental
status. The mortality and etiology of SE vary with age,
as do the incidence of some side effects such as hypoten-
sion. Therefore, the secondary objective is a subgroup
analysis to determine the most effective and/or the least
effective treatment for benzodiazepine-refractory SE in
children. The final objective is a comparison of three
drugs with respect to secondary outcomes: time to termi-
nation of clinical seizures (i.e., response latency), and
rates of intubation, admission to intensive care unit
(ICU), and mortality. Cessation of SE and occurrence of
serious adverse effects will be analyzed separately.
Methods
This is a multicenter, randomized, allocation-con-
cealed, Bayesian adaptive, phase III comparative effec-
tiveness trial of three active treatments in patients with
benzodiazepine-refractory status epilepticus (ESE).
Response-adaptive randomization will be used to allocate
patients to fPHT, LVT, or VPA for the treatment of SE in
the emergency department (ED), with the goal of focusing
randomization preferentially on the treatment arms with
the highest response rates. Initial randomization will be
1:1:1 and response-adaptive randomization will occur
after 300 patients have been recruited. Randomization will
be stratified by three age groups, 2–18, 19–65, and 66 and
older. Each subject will be followed until hospital
discharge or 30 days from enrollment if still hospitalized.
We expect to enroll up to 795 patients over 4 years, an
accrual rate of approximately 16.5 patients per month.
Patients will be enrolled by two national networks of
emergency departments: Neurology Emergency Treat-
ment Trials network (NETT) and Pediatric Emergency
Care and Applied Research Network (PECARN). Each
network has successfully undertaken a SE treatment trial
under Exception from Informed Consent (EFIC) rules.
Inclusion
We will include patients older than 2 years of age with
witnessed, clinically apparent seizures in the ED for at
least 5 min after receiving an adequate dose of ben-
zodiazepines for generalized, tonic–clonic convulsion(s).
Adequate doses of benzodiazepines for this study are:
diazepam 10 mg intravenous (IV), lorazepam 4 mg IV, or
midazolam 10 mg IV or intramuscular (IM) for subjects
>40 kg; and diazepam 0.3 mg/kg IV, lorazepam
0.0.1 mg/kg IV, or midazolam 0.3 mg/kg IV or IM for
subjects between 10 and 40 kg. These drugs may have
been administered in two or more divided doses, including
in the out-of-hospital setting.
Interventions and Duration
The study drugs will be formulated in the following
strengths: fPHT 16.66 mg/ml, VPA 33.33 mg/ml, and
LVT 50 mg/ml so as to allow identical infusion times in
order to maintain blinding. The drug will be produced,
packaged, and labeled by the University of California,
Davis, and shipped to the study sites. Medications will be
placed in prerandomized study boxes kept in an ED medi-
cation refrigerator. Each study box will contain a device
for real-time recording of medication allocation, study
procedure times, and outcomes. The iPOD (Apple, Cuper-
tino, CA, U.S.A.) will also provide alarms to remind staff
of upcoming study procedures. Any patient with wit-
nessed seizures in the ED will be evaluated for enrollment
based on inclusion and exclusion criteria. Enrollment will
occur using the EFIC for Emergency Research because of
the emergent and life-threatening nature of SE. Randomi-
zation will be stratified by age groups: 2–18, 19–65, and
66 years and older.
This is an intention-to-treat study. Enrollment occurs
when the infusion pump connected to study drug vial and
patient’s IV catheter is switched on and the time of
enrollment is recorded on the study device. The assigned
treatment dose (fPHT 20 mg/kg, LVT 60 mg/kg, or VPA
40 mg/kg) will be infused over 10 min. The patients will
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be observed for 20 min, at which time the duration of clin-
ical seizures and response to verbal or painful stimuli will
be recorded. At 60 min from enrollment, a study team
member will record whether a clinically apparent seizure
requiring intervention has occurred, whether there has
been improvement in mental status since the last observa-
tion, and whether life-threatening hypotension or arrhyth-
mias requiring intervention have occurred. Based on
response to these questions, the primary outcome will be
determined and recorded at this time. A subsequent chart
review will determine duration of clinical seizures, admis-
sion to ICU or floor, whether patient was intubated, and
final disposition.
Sample Size and Analysis
Based on a recent study (Alvarez V et al., 2011) and
expert evaluation of all currently published data on the
treatment of ESE, we assumed that the worst drug will be
effective in 50% of the patients. The recently completed
Rapid Anticonvulsant Medications Prior to Arrival Trial
(RAMPART) study for the initial treatment of SE was
conducted designed with the assumption that an absolute
difference of 10% or less would be considered nonclini-
cally significant (i.e., the noninferiority margin). There is
broad consensus among experts that a difference of 15%
would indicate superiority of one of the drugs over others,
and will be sufficient to change clinical practice; there-
fore, the study is powered to detect a 15% difference on
the whole study population in response rates.
The posterior probabilities that each treatment is the
most and least effective treatment will be calculated
using Bayesian methods based on a uniform prior for
each treatment’s success rate, and a conjugate beta-bino-
mial model (Connor et al., 2013). This trial will be con-
sidered a success if the probability that a treatment is the
most effective is >0.975 or the probability that a treat-
ment is the least effective is >0.975 for any treatment. A
sample size of 795 provides 90% power to identify the
most effective and/or the least effective treatment when
one treatment arm has a true response rate of 65% and
the true response rate is 50% in the other two arms. The
false-positive rate of this trial is the probability of identi-
fying either the most or the least effective treatment,
when in truth there is no difference between the arms.
Under simulation, the false-positive rate was determined
to be <0.05 under a variety of scenarios. The simulation
details have been published elsewhere (Connor et al.,
2013).
Randomization will be stratified by the following age
groups: 2–18, 19–65, and 66 and older. Midway through
the trial after 300 patients are enrolled, the randomiza-
tion of future patients will also depend on the responses
of patients randomized earlier. Future patients will be
more likely to be randomizaed to the treatment that has
the highest success rate, has imprecise effect estimates,
or has fewer patients randomized to it thus far. The
posterior probabilities that each treatment is the most
and least effective treatment will be calculated using
Bayesian methods based on a uniform prior for each
treatment’s success rate, and a conjugate beta-binomial
model.
Early stopping may occur at interim analyses conducted
after 400, 500, 600, and 700 patients are enrolled. At an
interim look, if the probability a single therapy offers the
highest success rate is >97.5% then the trial will be
stopped early for success. At an interim look, if the predic-
tive probability of trial succcess is <5%, the trial will be
stopped for futility.
This trial will be considered a success if the probability
that a treatment is the most effective is >0.975 or the prob-
ability that a treatment is the least effective is >0.975 for
any treatment. When the total sample size is 795, there
will be 90% power to identify the most effective and/or
the least effective treatment when one treatment arm has a
true response rate of 65% and the true response rate is
50% in the other two arms (as determined by simulation).
The secondary goal is to detect an absolute difference in
proportions as small as 20% between treatments in chil-
dren with at least 80% power. To detect this difference, a
sample size of 336 children is required.
Early stopping may occur at interim analyses at 400,
500, or 600 patients. If ever the probability a single ther-
apy offers the highest success rate is >97.5% then the trial
stops early for success. If ever the predictive probability
of trial succcess is <5%, the trial stops for futility.
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